400 PROFESSIONAL DR, SUITE 400, GAITHERSBURG, MD
Annual Report to Security Holders
Announces Appointment of John D. Fowler, Jr. to Board of Directors
Reports Fourth Quarter and Full Year 2025 Financial Results
Investor Presentation
Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
Reports Third Quarter 2025 Financial Results
FY 2025
Q3
Q2
Q1
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement
S-8 POS
Definitive Revised Proxy Statement